What is the consensus rating for QUCY stock?
The consensus rating for MAINZ BIOMED NV (QUCY) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.
MAINZ BIOMED NV (QUCY) Forecast, Price Target & Analyst Ratings
NASDAQ:QUCY • NL0015000LC2
Current stock price
0.5076 USD
0 (-0.45%)
At close:
0.482 USD
-0.03 (-5.04%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MAINZ BIOMED NV (QUCY).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $0.51 to mean target of N/A, Based on 7 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
QUCY was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about QUCY.
In the previous month the buy percentage consensus was at a similar level.
QUCY was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 895.5K 68.96% | 894K -0.17% | 537.1K -39.92% | 936.36K 74.34% | 2.542M 171.48% | 30.765M 1,110.27% | -100.00% | |||||
| EBITDA YoY % growth | -25.778M 1.35% | -17.401M 32.50% | -12.883M 25.96% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -26.645M -0.51% | -18.418M 30.87% | -13.499M 26.71% | -19.441M -44.02% | -23.365M -20.18% | -9.783M 58.13% | -17.992M -83.91% | -19.444M -8.07% | -20.604M -5.96% | -21.84M -6.00% | -23.159M -6.04% | |
| Operating Margin | -2,975.40% | -2,060.20% | -2,513.27% | -2,076.25% | -919.16% | -31.80% | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -48.05 31.13% | N/A 63.45% | N/A 83.39% | -1.38 52.80% | -1.50 -8.89% | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
225.57%
Revenue Next 5 Year
-14.87%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A